$ABOS SEC Filings

Filed On	Filing
26 Oct 2026	S-3
26 Oct 2026	10-Q
26 Oct 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure NEWTON, Mass., Oct. 26, 2026 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for ...
16 Sep 2026	8-K: Regulation FD Disclosure Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projec...
12 Aug 2026	DRS
12 Aug 2026	S-8
12 Aug 2026	10-Q
12 Aug 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
17 Jun 2026	Form 4: Porter Derrell, Director Received 6,460 shares by exercise or conversion ($6.91K) · Sold 6,460 shares ($15.1K) · Sold 12,800 shares ($29.8K) · 2 more
17 Jun 2026	144
16 Jun 2026	144
16 Jun 2026	8-K: Regulation FD Disclosure; Other Events
15 Jun 2026	144
10 Jun 2026	Form 4: Fountain Nathan B, Director Sold 6,400 shares ($14.3K)
09 Jun 2026	144
05 Jun 2026	Form 4: Ra Capital MANAGEMENT, L.p., Director and 4 others Received 35,500 shares as a grant or award · Granted 53,250 Stock Option (Right to Buy)
05 Jun 2026	Form 4: Fountain Nathan B, Director Received 35,500 shares as a grant or award · Granted 53,250 Stock Option (right to buy)
05 Jun 2026	Form 4: Drapkin Kimberlee C, Director Received 35,500 shares as a grant or award · Granted 53,250 Stock Option (right to buy)
05 Jun 2026	Form 4: Stalfort John A Iii, Director Received 35,500 shares as a grant or award · Granted 53,250 Stock Option (right to buy)
05 Jun 2026	Form 4: Porter Derrell, Director Received 35,500 shares as a grant or award · Granted 53,250 Stock Option (right to buy)

Comments